eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
6.44
+0.24 (3.96%)
At close: Sep 18, 2026, 4:00 PM EDT
6.44
+0.01 (0.08%)
After-hours: Sep 18, 2026, 6:34 PM EDT
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
59.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 151.18M |
| Xilio Therapeutics | 64.09M |
| MindWalk Holdings | 11.57M |
| Hyperion DeFi | 1.40M |
| ImageneBio | 800.00K |
| Serina Therapeutics | 130.00K |
| INmune Bio | 50.00K |
| Impact BioMedical | 35.00K |
EXOZ News
- 11 days ago - eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT - Accesswire
- 25 days ago - eXoZymes Inc trading resumes - TheFly
- 25 days ago - eXoZymes Inc trading halted, volatility trading pause - TheFly
- 4 weeks ago - eXoZymes Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - eXoZymes Quarterly report: Q2 2026 - Filings
- 4 weeks ago - eXoZymes Earnings release: Q2 2026 - Filings
- 4 weeks ago - eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today - Accesswire
- 4 weeks ago - eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - Accesswire